Skip to main content

Table 1 Model Inputs

From: Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Parameters

Base value

Distribution

Range

Source

Drug costs ($)

    

Sintilimab (100 mg)

166.92

Gamma

133.54-166.92

[20]

Bevacizumab biosimilar (100 mg)

177.13

Gamma

123.99-177.13

[20]

Lenvatinib (4 mg)

16.69

Gamma

11.68–16.69

[20]

Subsequent treatment ($)

    

Sintilimab + Bevacizumab

442.29

Gamma

353.83-530.74

[6]

Lenvatinib

631.81

Gamma

505.45-758.17

[6]

End-of-life care ($)

2132.67

Gamma

888.10-6108.44

[21]

Cost of follow-up per visit ($)

    

Computer tomography

90.43

Gamma

64.91-146.83

Medical service price database of 11 provinces in China

Blood biochemistry

24.27

Gamma

13.76–38.02

Blood routine

1.58

Gamma

0.77–2.94

Urine routine

0.67

Gamma

0.15–1.39

Myocardial enzyme test

5.13

Gamma

3.09–7.73

alpha feprotein test

3.18

Gamma

2.16–4.64

Cost of drug administration ($)

    

Diagnosis

5.13

Gamma

3.09–7.73

Medical service price database of 11 provinces in China

Intravenous injection

1.73

Gamma

0.46–4.64

Nursing

1.27

Gamma

0.77–1.85

Bed

2.05

Gamma

1.64–2.47

Cost of AEs per event ($)

    

Hypertension

3.42

Gamma

2.73–4.10

Expert opinion

Proteinuria

22.10

Gamma

17.68–26.52

Expert opinion

Platelet count decreased

176.55

Gamma

141.24-211.86

Expert opinion

Elevated bilirubin

77.28

Gamma

61.82–92.74

Expert opinion

Elevated aspartate aminotransferase

77.28

Gamma

61.82–92.74

Expert opinion

HR (Sintilimab + Bevacizumab versus Lenvatinib)

 

PFS

0.856

Log-normal

0.798–0.910

[6, 9]

OS

0.618

Log-normal

0.546–0.708

[6, 9]

Probability of AEs (per cycle)*

    

Sintilimab + Bevacizumab

    

 Hypertension

0.72%

Beta

0.58-0.87%

[6]

 Platelet count decreased

0.33%

Beta

0.27-0.40%

[6]

Lenvatinib

    

 Hypertension

1.32%

Beta

1.06-1.58%

[9]

 Proteinuria

0.35%

Beta

0.28-0.41%

[9]

 Platelet count decreased

0.29%

Beta

0.23-0.35%

[9]

 Elevated bilirubin

0.40%

Beta

0.32-0.48%

[9]

 Elevated aspartate aminotransferase

0.29%

Beta

0.23-0.35%

[9]

Health state utility

    

PFS state

0.745

Beta

0.730–0.760

[17]

PP state

0.678

Beta

0.655–0.701

[17]

Disutility of AEs

    

Hypertension

-0.12

Beta

-0.10 to -0.14

[18]

Proteinuria

-0.12

Beta

-0.10 to -0.14

[18]

Decreased platelet count

0.00

Beta

0.00

[19]

Increased blood bilirubin

0.00

Beta

0.00

[19]

Elevated aspartate aminotransferase

0.00

Beta

0.00

[19]

Discount rate (per cycle)

0.28%

Beta

0.00-0.44%

 
  1. PFS: progression-free survival; PP: post-progression; AE: adverse event, OS: overall survival; HR: hazard ratio
  2. *Assumed the AEs occurred in first year